Table 2.
Baseline clinical characteristics of patients.
| Control (n = 59) |
PMR (n = 55) |
P | ||
|---|---|---|---|---|
| PAH diagnosis n (%) | Idiopathic | 26 (44.1) | 27 (49.1) | 0.87 |
| Congenital heart disease | 19 (32.2) | 16 (29.1) | ||
| Connective tissue disease | 14 (23.7) | 12 (21.8) | ||
|
| ||||
| PAH therapy n (%) | Monotherapy | 34 (57.6) | 30 (54.5) | 0.89 |
| Dual therapy | 20 (33.9) | 21 (38.2) | ||
| Triple therapy | 5 (8.5) | 4 (7.3) | ||
| Oxygen therapy | 23 (39.0) | 24 (43.6) | ||
|
| ||||
| PAH-targeted medication | ET receptor antagonists | 36 (61.0) | 35 (63.6) | 0.98 |
| Phosphodiesterase-5 inhibitors | 37 (62.7) | 36 (65.5) | ||
| Prostanoids | 10 (16.9) | 8 (14.5) | ||
| Calcium channel blockers | 9 (15.3) | 9 (16.4) | ||
|
| ||||
| Course of disease (years) | 7.9 ± 5.2 | 7.5 ± 5.4 | 0.65 | |
|
| ||||
| 6MWD (meters) | 374.9 ± 136.2 | 368.2 ± 143.5 | 0.87 | |
|
| ||||
| WHO functional class n (%) | I | 3 (5.1) | 2 (3.6) | 0.92 |
| II | 24 (40.7) | 22 (40.0) | ||
| III | 32 (54.2) | 31 (56.4) | ||
|
| ||||
| Hypertension n (%) | 41 (69.5) | 37 (67.3) | 0.84 | |
|
| ||||
| COPD n (%) | 18 (30.5) | 19 (34.5) | 0.69 | |
|
| ||||
| Coronary heart disease n (%) | 15 (25.4) | 12 (21.8) | 0.67 | |
|
| ||||
| Type II diabetes mellitus n (%) | 11 (18.6) | 9 (16.4) | 0.81 | |
|
| ||||
| Sleep apnea n (%) | 9 (15.3) | 10 (18.2) | 0.80 | |
Note: for continuous variables, all values were expressed as mean ± SD and Student's t-tests were performed to compare means between the groups. For categorical variables, all values were expressed as n (%) and comparisons were performed with Chi-square tests. PAH: pulmonary arterial hypertension; 6MWD: 6-minute walk distance; WHO: World Health Organization; ET: endothelin; COPD: chronic obstructive pulmonary disease.